TG Therapeutics | TGTX - Net Income


TG Therapeutics reported $390.9M in Net Income for its fiscal quarter ending in September of 2025.





Net Income Change Date
AbbVie USD 1.82B 1.63B Dec/2025
Alaunos Therapeutics USD -1.16M 417K Sep/2025
Amgen USD 1.33B 1.88B Dec/2025
Ardelyx USD -969K 18.11M Sep/2025
Arrowhead Research USD 30.81M 54.56M Dec/2025
Bayer EUR -963M 764M Sep/2025
Biogen USD 466.5M 168.3M Sep/2025
Corcept Therapeutics USD 19.67M 15.48M Sep/2025
Dynavax Technologies USD 18.72M 114.82M Jun/2025
Gilead Sciences USD 3.05B 1.09B Sep/2025
J&J USD 5.12B 36M Dec/2025
Novartis USD 3.93B 96M Sep/2025
PTC Therapeutics USD 15.9M 80.75M Sep/2025
Regeneron Pharmaceuticals USD 844.6M 615.4M Dec/2025
Roche Holding CHF 5.47B 1.76B Dec/2025
TG Therapeutics USD 390.9M 362.71M Sep/2025
Vertex Pharmaceuticals USD 1.08B 50M Sep/2025